Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement
Kyverna Therapeutics Inc KYTX
$7.30
▼ -2.54%
($-0.19)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$7.52
Prev Close
$7.49
Day Range
$7.13 – $7.61
52W Range
$2.80 – $13.67
Market Cap
$443.81M
Beta
1.83
EPS (TTM)
$-3.28
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-08 |
| Shares Out. | 60,800,000 |
| Website | kyvernatx.com/ ↗ |
| Phone | 15106268331 |
| Employees | 129 |
| Net Income | -$39.7M |
| Free Cash Flow | -$150.4M |
| Total Assets | $257.0M |
| Total Liabilities | $61.4M |
| Equity | $195.6M |
About Kyverna Therapeutics Inc
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics Inc is a publicly traded company under the ticker symbol KYTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)
📰 Latest News for KYTX
Kyverna Therapeutics shares are trading higher after the company and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, autologous CD19-directed CAR T-cell therapy.
Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy